News|Articles|January 18, 2024

Clinician Wellness in Psychiatric Times

Take a look back at our recent coverage relating to our January content theme.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Cultural Competency and Community Engagement in Psychiatric Practice

ByNaomi Dambreville, PhD

August 21st 2026

Objective Measurement for Psychiatry: Universal Brain's ERP System

ByKazu Okuda, MD

August 20th 2026

Psychiatry Mid-Year Market Update 2026: Persistent Demand, Widening Valuation Gap, and Workforce/Regulatory Realities

BySteve Grassa

August 6th 2026

Reframing the Side Effect: Walter Brown, MD, on Placebo and Nocebo

ByJoseph F. Goldberg, MD,Walter A. Brown, MD

July 31st 2026

What Does Interventional Psychiatry Actually Mean? Reframing Non-Standard Treatments for Depression

ByLara Shirikjian, MD

July 31st 2026

Latest CME

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clinician Wellness in Psychiatric Times

Related Content

Cultural Competency and Community Engagement in Psychiatric Practice

Objective Measurement for Psychiatry: Universal Brain's ERP System

Psychiatry Mid-Year Market Update 2026: Persistent Demand, Widening Valuation Gap, and Workforce/Regulatory Realities

Reframing the Side Effect: Walter Brown, MD, on Placebo and Nocebo

What Does Interventional Psychiatry Actually Mean? Reframing Non-Standard Treatments for Depression

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Migraine and Psychiatric Comorbidities

Skin and Psych: Using Habit Loop Science to Interrupt the Itch-Scratch Cycle, With Judson Brewer, MD, PhD

FDA Clears First and Only Single-Biomarker Blood Test for Alzheimer Disease Assessment

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

Exploitation of Individuals With Psychosis